[go: up one dir, main page]

NI201000067A - Intermediarios de gsm. - Google Patents

Intermediarios de gsm.

Info

Publication number
NI201000067A
NI201000067A NI201000067A NI201000067A NI201000067A NI 201000067 A NI201000067 A NI 201000067A NI 201000067 A NI201000067 A NI 201000067A NI 201000067 A NI201000067 A NI 201000067A NI 201000067 A NI201000067 A NI 201000067A
Authority
NI
Nicaragua
Prior art keywords
intermediaries
gsm
compounds
useful
secretase
Prior art date
Application number
NI201000067A
Other languages
English (en)
Inventor
Yung Ho Chih
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201000067A publication Critical patent/NI201000067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se relaciona al uso de compuestos que tienen la Fórmula general I, en donde las definiciones o R1, y R2 se proporcionan en la especificación. Dichos compuestos de la Fórmula I son útiles para la síntesis de una variedad de moduladores de la y-secretasa, que a su vez son útiles para el tratamiento de las enfermedades asociadas con actividad de la y-secretasa, incluyendo la enfermedad de Alzheimer.
NI201000067A 2007-10-19 2010-04-16 Intermediarios de gsm. NI201000067A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98125707P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
NI201000067A true NI201000067A (es) 2010-09-13

Family

ID=40092042

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000067A NI201000067A (es) 2007-10-19 2010-04-16 Intermediarios de gsm.

Country Status (16)

Country Link
US (1) US20090306392A1 (es)
EP (1) EP2209764A1 (es)
JP (1) JP2011500720A (es)
KR (1) KR20100081350A (es)
CN (1) CN101903334A (es)
AU (1) AU2008312362A1 (es)
BR (1) BRPI0817789A2 (es)
CA (1) CA2702911A1 (es)
CO (1) CO6270355A2 (es)
CR (1) CR11449A (es)
EA (1) EA201070497A1 (es)
IL (1) IL205040A0 (es)
MX (1) MX2010004311A (es)
NI (1) NI201000067A (es)
WO (1) WO2009052341A1 (es)
ZA (1) ZA201003521B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101896452B (zh) * 2007-10-19 2013-07-31 詹森药业有限公司 连接有碳的γ-分泌酶调节剂
KR101569391B1 (ko) * 2007-10-19 2015-11-16 얀센 파마슈티카 엔.브이. γ-세크레타아제의 피페리디닐 및 피페라지닐 조절제
AU2008312371B2 (en) * 2007-10-19 2013-06-20 Janssen Pharmaceutica, N.V. Amine linked modulators of gamma-secretase
CN105646452B (zh) * 2015-12-24 2018-05-01 北京康立生医药技术开发有限公司 一种蛋白激酶抑制剂的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
EP1650183A1 (en) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
EP1847524B1 (en) * 2006-04-21 2009-10-14 Cellzome Limited Terphenyl derivatives for treatment of Alzheimer's disease
DE602006007810D1 (de) * 2006-04-21 2009-08-27 Cellzome Ltd Substituierte Biphenylcarbonsäuren und deren Derivate

Also Published As

Publication number Publication date
IL205040A0 (en) 2010-11-30
CO6270355A2 (es) 2011-04-20
AU2008312362A2 (en) 2010-07-08
BRPI0817789A2 (pt) 2015-03-24
EP2209764A1 (en) 2010-07-28
MX2010004311A (es) 2010-05-03
CN101903334A (zh) 2010-12-01
AU2008312362A1 (en) 2009-04-23
WO2009052341A1 (en) 2009-04-23
JP2011500720A (ja) 2011-01-06
KR20100081350A (ko) 2010-07-14
EA201070497A1 (ru) 2010-12-30
CA2702911A1 (en) 2009-04-23
US20090306392A1 (en) 2009-12-10
ZA201003521B (en) 2011-08-31
CR11449A (es) 2011-01-14

Similar Documents

Publication Publication Date Title
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UY29112A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
UY30052A1 (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200500360A (es) Compuestos organicos
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
CR11447A (es) Moduladores de piperidinil y piperazinil de y secretasa
NO20076405L (no) Anvendelse av 24-nor-UDCA
UY29417A1 (es) Agentes endoparasiticidas
GT200700097A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
NI201000067A (es) Intermediarios de gsm.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY29036A1 (es) Derivados de oxopiperidina, su preparacion y su aplicacion en terapeutica
EA201070496A1 (ru) УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas
EA201070494A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ